{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T15:40:03Z","timestamp":1745595603934,"version":"3.40.4"},"reference-count":4,"publisher":"BMJ","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Case Reports"],"published-print":{"date-parts":[[2009]]},"abstract":"<jats:p>A middle-aged woman was referred under the 2-week urgent brain cancer initiative following the finding of a raised serum prolactin level. The patient had been taking metoclopramide on a daily basis to aid her symptoms of irritable bowel syndrome. The raised prolactin level had led to oligomenorrhoea prompting her general practitioner (GP) to check pituitary hormone levels.<\/jats:p><jats:p>Metoclopramide is a potent dopamine antagonist and dopamine acts as the physiological inhibitor of prolactin synthesis. Thus, the dopamine antagonism led to elevated prolactin level and the symptom of oligomenorrhoea.<\/jats:p><jats:p>Following curtailment of the metoclopramide, the prolactin level normalised very quickly and the patient was reassured.<\/jats:p><jats:p>Consideration should be given to non-pathological causes of hyperprolactinaemia, including physiological states such as pregnancy and concurrent medication.<\/jats:p>","DOI":"10.1136\/bcr.01.2009.1432","type":"journal-article","created":{"date-parts":[[2009,12,4]],"date-time":"2009-12-04T03:45:57Z","timestamp":1259898357000},"page":"bcr0120091432","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacological hyperprolactinaemia: Table 1"],"prefix":"10.1136","volume":"2009","author":[{"given":"Maithili","family":"Srikantha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Butterworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2009,12,3]]},"reference":[{"key":"2025042508210092000_2009.dec03_1.bcr0120091432.1","unstructured":"Warrell DA Cox TM Firth JD . Oxford textbook of medicine. 4th edn. Oxford, UK: Oxford University Press, 2004."},{"key":"2025042508210092000_2009.dec03_1.bcr0120091432.2","unstructured":"Kumar P Clark M . Kumar and Clark clinical medicine. 6th edn. Philadelphia, Pennsylvania, USA: Saunders, 2005."},{"key":"2025042508210092000_2009.dec03_1.bcr0120091432.3","unstructured":"Rang HP Dale MM Ritter JM . Pharmacology. 5th rev edn. London, UK: Churchill Livingstone, 2003."},{"key":"2025042508210092000_2009.dec03_1.bcr0120091432.4","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199703000-00006"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr.01.2009.1432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T15:21:12Z","timestamp":1745594472000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr.01.2009.1432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":4,"alternative-id":["10.1136\/bcr.01.2009.1432"],"URL":"https:\/\/doi.org\/10.1136\/bcr.01.2009.1432","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2009]]}}}